• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Study on susceptibility of multiding resistans cells toward adivated lymphocytes

Research Project

Project/Area Number 07672196
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Surgical dentistry
Research InstitutionKanagawa Dental College

Principal Investigator

SASAKURA Yuuichi  Kanagawa Dental Collge, School of dentistry, Assistant Professor, 歯科部, 講師 (80121002)

Co-Investigator(Kenkyū-buntansha) MUTSUZAWA Shuji  Kanagawa Dental Collge, School of dentistry, Instractor, 歯科部, 助手 (70229459)
MATSUMOTO Goichi  Kanagawa Dental Collge, School of dentistry, Instractor, 歯科部, 助手 (60199867)
KOSE Akira  Kanagawa Dental Collge, School of dentistry, Instractor, 歯科部, 講師 (70215268)
Project Period (FY) 1995 – 1996
Project Status Completed (Fiscal Year 1996)
Budget Amount *help
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1996: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1995: ¥1,500,000 (Direct Cost: ¥1,500,000)
Keywordsanti-tumor drug resistans / LAK cell / P-glycoprotein / LAK / p-glycoprotein / MRK-16モノクロナル抗体 / CD16抗原陽性細胞
Research Abstract

It has been reported that IL-2 induced LAK cells showed the high value of cytotoxicity against antitumor drug resistant cells expressed P-glycoprotein (P-gp). However, it remains unclear that LAK cells are able to recognize the P-gp on certain tumor cell surface. We examined the difference of susceptibility between expressed and non-expressed P-gp, and determined a sort of the population in LAK cells which play a pivotal role in cytotoxicity, In addition, we estimated the relationship between susceptibility of the tumor cells and expression of P-gp or other antigens on their surface toward LAK cells.
[Materials and methods] Target cells : CEM cells (leukemia), KB cells (oral squamous cell carcinoma) and theseresistant cells (CEM/VLB0.1, CEM/VLB1.0 ; P-gp expressed, KB/BLM1.0, KB/CDDP1.0 ; P-gp non-expressed) were used. Effector cells : peripheral blood mononuclear cells of each volunteers cultured with IL-2 (1,000U/ml) for 4days, and then CD16^+ and CD8^+ cells were isolated from unfractionated LAK cells. Cytotoxicity assay : ^<51>Cr release was measured. Flow cytometric analysis : P-gp, MHC class I,class II,LFA-1,2,3ICAM-1, CD44 and Fas were determind on tumor cell surface. Blocking assay : Target cells were treated with anti-MHC class I,CD44 or MRK16 (anti P-gp) mAb.
[Resuls] Unfractionated LAK cells showed significant higher cytotoxicity to non-expressed P-gp more than thier parent cells. CD16^+-LAK cells play a pivotal role to kill CEM/VLB,CD8^+-LAK cells showed higher cytotoxicity to KB/CDDP1.0. The susceptibility of anti-tumor drug resistant cells expressed P-gp were not inhibited by MRK16. In KB/BLM1.0 and KB/CDDP1.0, the susceptibility showed relationship with MHC class I,ICAM-1.
[Discussion] It was suggested that the susceptibility of the tumor cells were not associated with P-gp. These results indicate that efector cells are various population. The susceptibility is depend on a sort of the tumor cells and on the anti-tumor drug.

Report

(3 results)
  • 1996 Annual Research Report   Final Research Report Summary
  • 1995 Annual Research Report
  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] 平田量哉: "抗癌剤耐性腫瘍細胞に対するLAK細胞の抗腫瘍効果(第1報)" 日本口腔科学会雑誌. 45. 592-593 (1996)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1996 Final Research Report Summary
  • [Publications] 平田量哉: "抗癌剤耐性口腔癌および白血病細胞に対するLAK細胞の抗腫瘍効果" 消化器と免疫. 33. (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1996 Final Research Report Summary
  • [Publications] 平田量哉: "抗癌剤耐性腫瘍細胞に対するLAK細胞の抗腫瘍効果(第1報)" 日本口腔科学会雑誌. 45. 592-593 (1996)

    • Related Report
      1996 Annual Research Report
  • [Publications] 平田量哉: "抗癌剤耐性口腔癌および白血病細胞に対するLAK細胞の抗腫瘍効果" 消化器と免疫. 33. (1997)

    • Related Report
      1996 Annual Research Report

URL: 

Published: 1995-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi